Skip to main content

Chronic Venous Disease

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Hanlim Pharm
Hanlim PharmKorea - Seoul
1 program
1
Entelon Tab.150mgPhase 41 trial
Active Trials
NCT04882228Unknown278Est. Feb 2022
InterVene
InterVeneCA - Redwood City
1 program
mechanical thrombectomyN/A1 trial
Active Trials
NCT07529756Not Yet Recruiting86Est. Mar 2029
Servier
ServierFrance - Suresnes
1 program
to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVDN/A1 trial
Active Trials
NCT05612217Completed433Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Hanlim PharmEntelon Tab.150mg
InterVenemechanical thrombectomy
Servierto estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD

Clinical Trials (3)

Total enrollment: 797 patients across 3 trials

NCT04882228Hanlim PharmEntelon Tab.150mg

Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)

Start: Jan 2021Est. completion: Feb 2022278 patients
Phase 4Unknown
NCT07529756InterVenemechanical thrombectomy

The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry

Start: Jun 2026Est. completion: Mar 202986 patients
N/ANot Yet Recruiting
NCT05612217Servierto estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD

Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD

Start: Dec 2022Est. completion: Apr 2024433 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.